Hi, I'm not sure if you get my previous message. Yesterday I send my article to you to get edit but, it was a wrong one and I can't retract it. Below is the one I'd like you to edit. Can you edit this one? thank you.

Since the beginning of 2012, the biotech sector has been on the rise and Gilead Sciences Inc. (Gild) is no exception. GILD has seen a big jump in its prices and already has gained over 50 percents year-to-date, it seem that everytime I turned around GILDs stock just tick up higher everyday. Right now, I still see GILD as an attractive buy, especially if you're a long-term investor. As the world population increases and a growing number of people getting older, there will always be a need for more and better medicines. People are striving to live longer and healthier lives; therefore, I believe GILD will continue to benefit for many years to come. I'd like to recommend you to add GILD to your portfolio. Because of its vast products pipeline and the diseases they're targeting, I expect Gilead Sciences will continue to do well in the long-term and will benefit investors going forward.
 
Gilead is a research-based biopharmaceutical company that is aiming to treat life-threatening illnesses around the world. Gilead's products pipeline treats viral infections such as HIV / AIDS, hepatitis B and C, severe chronic conditions such as respiratory and cardiovascular conditions, and cancer. To date, there are no cures for these conditions. Gilead knows how important it is for those who are affected by these diseases to find effective treatments, and they make it their priority to assist those patients. Gilead is also working with federal and state patient-assistance programs to ensure all patients have access to their medications. From their beliefs and seeing that GILD is a company that has the right philosophy to help people who need proper care, it almost gives me enough reason to want to invest in their company. So, because of their research and development, and determination to find the cure for these life-threatening diseases, I believe
Gilead is a good investment in the long-term.
 
In January 2012, Gilead acquired Pharmasset for $11 billion. With its acquisition of Pharmasset, GILD has been able to develop the first all-oral Hepatitis C virus (HCV) regimen (Sofosbuvir), which will benefit approximately 3.2 million people world wide. On April 8, 2013 Gild has submitted a New Drug Application to the U. S. Food and Drug Administration (FDA) for Sofosbuvir to treat HCV infection. In phase 3 clinical trial Sofosbuvir has shown a significant efficacy rate for genotypes 2 and 3. For genotypes 1, 4, 5, and 6 patients who are on a 12-week all-oral treatment when used in combination with Ribavirin (RBV) and Pegylated Interferon ( peg-IFN ) are considered cured of their HCV infection. That's an essential for GILD considering that there isn't any drug out there to treat HCV that has proven significant result as Sofosbuvir. Now if the FDA would approve Sofosbuvir, which I think they will soon, due to its positive clinical trial results,
Sofosbuvir will be a very important milestone for GILD. Sofosbuvir will be a significant addition to their products pipeline and will extensively help increase their revenue growth in 2014 and beyond. 
 
 
In addition to Sofosbuvir, in the field of cancer, GILD has developed another important drug Idelalisib to treat Chronic Lymphocytic Leukemia. It works by blocking the production of P13-K delta proteins that are overactive in B cell lymphoma. Already Idelalisibs phase 2 study has shown some promising response rate for previously untreated Chronic Lymphocytic Leukemia (CLL), which is the second most common form of leukemia in the US. Currently CLL is being treated with Rituximab and combined with chemotherapy ( Rituximab is developed by Idec Pharmaceutical and co-marketed with Genetech). With the positive data results in phase 2, I believe Gild can perfect Idelalisib in phase 3 of their clinical trial and should receive FDA approval soon. Idelalisib will help Gileads revenue significantly once the medication is approved and commercialized.
 
What I also like about Gilead, in addition to its pipeline, is that it's a profitable biopharmaceutical company with a strong balance sheet. It can, and has enough cash flow to support its research and drug development in order to bring new products to the market. Currently, Gilead has a portfolio of 15 marketed products not including Sofosbuvir and Idelalisib, which they sell on their own or through various partnerships. At the end of 1Q March 31, 2013 Gild has $2.63 billion in cash, an increase of $50 million, from its $2.58 billion in 4Q December 31, 2012. Before it acquired Pharmasset for $11 billion, Gild had $9.96 billion as of Dec. 31, 2011. Also Gilead has a 5-year annual revenue growth rate of 18%. My point of all these numbers is that GILD can, and has the capability to make money from quarter to quarter and year to year. 
 
Because of the fact that it has a positive cash flow and of its varied research in different fields of medicines, I believe Gilead Sciences will continue to grow. With over $2.63 billion in cash and their latest acquisition of Pharmasset, and two exciting drugs that's awaiting to get FDA approval ( Sofosbuvir and Idelalisib), I'm sure many more acquisition and new drugs are to come in the future. I'm behind Gilead as a long-term buy. At this price level, because of its rich pipeline and considering it's also a profitable biopharmaceutical company I think GILD has more upside momentum. I wouldn't worry about timing when to get in on Gilead. I look at Gilead as a good, classic example of a stock that you'd like to dollar-average in and hold it for few years. And any pull back I would see it as a good opportunity to buy more. I'd recommend buying it now and adding more when the opportunity arises.